Rezolute's HI Treatment Faces FDA Scrutiny Despite Encouraging Data
Event summary
- Rezolute held a Type B meeting with the FDA on March 17, 2026, regarding its Phase 3 sunRIZE trial for ersodetug.
- The sunRIZE trial failed to meet its primary endpoint despite demonstrating consistent, clinically significant improvements in hypoglycemia events.
- The FDA acknowledged potential behavioral factors may have confounded the trial results and suggested independent review of study data.
- Rezolute believes target drug concentrations were achieved and biomarker responses indicate pharmacologic activity.
The big picture
Rezolute's ersodetug represents a potentially significant advancement in treating congenital hyperinsulinism, a rare and debilitating condition. However, the FDA's cautious response highlights the challenges inherent in clinical trials for rare diseases, particularly when behavioral factors can significantly impact results. The outcome underscores the increasing scrutiny of clinical trial methodology and data integrity within the pharmaceutical industry, demanding greater transparency and rigor in drug development.
What we're watching
- Regulatory Headwinds
- The FDA’s insistence on independent data review signals potential hurdles for approval, requiring Rezolute to proactively address concerns about trial design and data interpretation.
- Clinical Trial Design
- Future trials will need to incorporate strategies to mitigate behavioral factors and improve the reliability of hypoglycemia measurement, potentially increasing trial complexity and cost.
- Execution Risk
- The timeline for a marketing application remains uncertain, hinging on the FDA’s review and Rezolute’s ability to provide convincing evidence of efficacy, which could delay revenue generation.
Related topics